XNAS
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2025-11-06 | Q3 2025 | -0.59 | -0.21 | +64.41% | $0 | ✅ Beat | — | — | — |
| 2025-03-11 | Q4 2024 | -1.98 | -2.01 | -1.52% | $0 | ❌ Miss | -1.84% | +11.32% | -73.81% |
| 2024-11-13 |
| Q3 2024 |
| -1.95 |
| -1.87 |
| +4.10% |
| $0 |
| ✅ Beat |
| -0.85% |
| -4.26% |
| +3.41% |
| 2024-08-13 | Q2 2024 | -1.90 | -1.86 | +2.11% | $0 | ✅ Beat | +1.93% | +3.54% | +1.29% |
| 2024-05-14 | Q1 2024 | — | -1.84 | — | $0 | — | -1.79% | -3.83% | -15.82% |
| 2024-03-26 | Q4 2023 | — | -3.57 | — | $0 | — | — | — | — |
| 2023-12-14 | Q3 2023 | — | -3.07 | — | $0 | — | -4.99% | +1.39% | +28.25% |
Showing last 7 quarters.